Mylan collaborates with CSIR for management of COVID-19

▴ clinical-trials-well-proven-drugs-partnership-industry-towards-development-multiple-therapeutic-options-covid19
A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration

The Council of Scientific & Industrial Research (CSIR), India’s premier research organization, and Mylan Laboratories Limited, the India-based subsidiary of leading global pharmaceutical company Mylan, today announced a partnership to address unmet patient needs amidst the evolving COVID-19 pandemic. Under the partnership, CSIR’s constituent laboratory Indian Institute of Chemical Technology (CSIR-IICT), and Mylan will collaborate to identify potential therapies for COVID-19.

A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration. The first of the clinical trial to be rolled out is a multiple arm phase 3 study that will be conducted in adult patients with mild to moderate COVID -19 at risk of complications.

Director-General of CSIR, Dr Shehkar C Mande stated, “The current collaboration with Mylan is a significant milestone and during the current COVID-19 pandemic, CSIR has prioritized conducting clinical trials of well-proven drugs in partnership with industry towards the development of multiple therapeutic options for COVID-19.”

Director of CSIR-IICT, Dr Chandrasekhar said, “CSIR is delighted to associate with Mylan as knowledge and scientific partner, and looks forward to working with the company, especially given Mylan’s vast industry experience in clinical trials and commercialization.”

Mylan Chief Operating Officer, Sanjeev Sethi stated, “Our collaboration with CSIR is a strategic step forward aimed at identifying effective treatments for patients with COVID-19. In addition to bringing forward new indications, this partnership will also help us identify multiple molecules that can potentially be leveraged in therapies for various other infectious diseases in the future.”

The application for the clinical trials has been submitted to the Drugs Controller General of India (DCGI) for regulatory approval.

CSIR has appointed Dr Ram Vishwakarma, Honorary Advisor to DG-CSIR and former Director CSIR-IIIM (Indian Institute of Integrative Medicine) as a mentor to lead this collaboration.

The Council of Scientific & Industrial Research (CSIR), known for its cutting-edge R&D knowledgebase in diverse Science & Technology areas, is a contemporary and premier R&D organization. Having a pan-India presence, CSIR has a dynamic network of 38 national laboratories, 39 outreach centres, 3 Innovation Complexes and 5 units. CSIR covers a wide spectrum of science and technology – from oceanography, geophysics, chemicals, drugs, genomics, biotechnology and nanotechnology to mining, aeronautics, instrumentation, environmental engineering and information technology.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. It is one of the world's largest producers of active pharmaceutical ingredients.

Tags : #Mylan #CSIR #DCGI #SanjeevSethi #LatestPharmaCollaboration #DrRamVishwakarma

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Exploring Mortality Risks for Lesbian and Bisexual Women: Key Findings from a Comprehensive Research EffortApril 29, 2024
Implications of Alcohol Intake During Pregnancy on Fetal Development: New Study Reveals Subtle ChangesApril 29, 2024
Indian Air Force's Night Vision Rescue: Soldier’s Life Saved in High-Stakes AirliftApril 29, 2024
Now You Can Also Buy Insurance For Your Parents Aged Above 65 years: IRDAI Lifts Age Cap for Health Insurance Expanding Healthcare AccessApril 29, 2024
Ensuring Infection Control: Central Government Hospitals Implement New Safety MeasuresApril 29, 2024
Dish TV Revolutionizes Entertainment with ‘Dish TV Smart+’ Services, Offering TV and OTT on Any Screen, AnywhereApril 26, 2024
Arohan Financial Services Recognized Among India's Best Workplaces in BFSI 2024April 26, 2024
Why Podcasts Are the Next Big Thing in Healthcare Advertising in IndiaApril 26, 2024
Challenges of Child Growth at High Altitudes: New Study Reveals ImpactApril 26, 2024
Staying Cool in India's Scorching Heat: Heatwave Safety TipsApril 26, 2024
The Dark Side of Neotame (Artificial Sweetener): New Research Raises Concerns about Gut HealthApril 26, 2024
Sightsavers India Fellowship Program Invites Applications for Promising OphthalmologistsApril 25, 2024
Transforming Brain Healthcare: India's Visionary Task Force for Neurological DisordersApril 25, 2024
The Battle Against Malaria: Rising Trends and Vaccine InnovationsApril 25, 2024
Talc and Asbestos Controversy: Inside Johnson & Johnson's Courtroom StruggleApril 25, 2024
The Hidden Struggles of Parenthood: Addressing Isolation, Loneliness, and BurnoutApril 25, 2024
FDA Confirms Bird Flu Virus Remnants in Pasteurized Milk: Safety and Regulatory InsightsApril 24, 2024
Sarvodaya Hospital Redefines Total Knee Replacement Surgery with Augmented Reality April 23, 2024
Fateh Education announces partnership to expand educational opportunities for Indian studentsApril 23, 2024
10 Strategies to counter disinformation for the healthcare digital ecosystemApril 23, 2024